Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558503 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
A Phase 2 study, sponsored by UroGen Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03558503 is a Phase 2 study that has completed, run by UroGen Pharma. The registered enrollment target is 63 participants.
The verdict
NCT03558503, a Phase 2 study, has completed, sponsored by UroGen Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This Phase 2b, single-arm, multicenter study evaluated the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).
Interventions
- DRUG UGN-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2020-10-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03558503
The ClinicalTrials.gov registry entry for NCT03558503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UroGen Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UGN-102 is the first listed.
NCT03558503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03558503 about?
NCT03558503 is a clinical study titled "A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer". This Phase 2b, single-arm, multicenter study evaluated the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).
What is the current status of trial NCT03558503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-10-15. Estimated completion is 2020-10-21.
What interventions are being tested in trial NCT03558503?
The interventions under investigation include: UGN-102 (DRUG).
Who is sponsoring clinical trial NCT03558503?
This trial is sponsored by UroGen Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.